General Clinical Research Center

全科临床研究中心

• 批准号: 7229536
• 负责人: ERIK L HEWLETT
• 金额: $ 460.5万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-05-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7229536
• 关键词: General; Clinical; Research; Center

EXCEED THE SPACE PROVIDED. Clinical investigation at the UVA GCRC is in its 31st year, and we request support for years 33-37. Our GCRC has longstanding strengths in neuroendocrinology, allergy, reproductive medicine, immunotherapy of cancer, and diabetes. These persist. In the past 2 years we have attracted a new cadre of GCRC investigators from Cardiology, vascular biology, and from the Center for Alternative Medicine program in the School of Nursing. With the recent recruitment of new research intensive leadership in our divisions of Cardiovascular Medicine, Hematology and Oncology, and our Department of Psychiatry and Behavioral Medicine, we anticipate continued growth and vitality of our research programs. In the past 2 years, we have also had major upgrades in our core assay program thereby facilitating sample throughput to >100,000/yr while freeing personnel time to implement additional analytical services. We have initiated a new GCRC imaging laboratory to allow studies of endothelial dysfunction in setting of diabetes, insulin resistance, and PCOS and microvascular perfusion in multiple organs including heart, muscle and kidney. The UVA GCRC has enjoyed an excellent record of productivity (>170 publications over the past 4 yrs). Its exercise, informatics and biomathematics cores have been national leaders in their innovative support for clinicalinvestigations. The GCRC enjoys a stable core of NIH-funded established investigators and is developing through our educational and mentoring programs another generation of skilled clinical investigators. We are particularly proud of our CAP and K award winners. During the last 3 years, we have seen (as has been a national trend) a growth in outpatient studies while inpatient studies, particularly those that have involved 24 hr blood sampling, have decreased. We have pro- actively begun working with the UVA Health System to plan a redesigned GCRC with expanded space and greater accessibility for outpatients that would accommodate current and projected usage.

超过空间 假如。 UVA GCRC进行的临床调查已有31年，我们要求支持33 - 37年。我们的 GCRC在神经内分泌学，过敏，生殖医学，免疫疗法方面具有长期的优势 癌症和糖尿病。这些坚持。在过去的两年中，我们吸引了GCRC的新干部 心脏病学，血管生物学和来自替代医学中心计划的研究者 护理学校。随着最近在我们的部门招募新的研究强化领导 心血管医学，血液学和肿瘤学以及我们的精神病学系 医学，我们预计我们的研究计划的持续增长和活力。在过去的两年中，我们 在我们的核心测定程序中也进行了重大升级，从而促进样本吞吐量 > 100,000/年，在释放人员时间来实施其他分析服务时。我们发起了一个新的 GCRC成像实验室允许在糖尿病，胰岛素抵抗，胰岛素抵抗的情况下研究内皮功能障碍 以及包括心脏，肌肉和肾脏在内的多个器官中的PCOS和微血管灌注。 UVA GCRC拥有出色的生产力记录（在过去的4年中> 170个出版物）。它是 锻炼，信息学和生物学核心一直是国家领导者的创新支持 临床评估。 GCRC享有NIH资助已建立的调查人员的稳定核心，并且 通过我们的教育和指导计划发展另一代熟练临床 调查人员。我们为我们的CAP和K奖得主特别自豪。 在过去的三年中，我们已经看到（这是国家趋势）在门诊研究中的增长，而 住院研究，尤其是涉及24小时血液采样的研究，已经减少。我们有亲 积极开始与UVA卫生系统合作，以扩大空间和 可以适应当前和预计用法的门诊病人的更大可访问性。